Neuroendocrine Tumors: Challenges and Future Perspectives (Second Volume)

Dear Colleagues,

Neuroendocrine tumors (NETs) are a family of neoplasms of increasing incidence and prevalence worldwide. Their heterogeneity in terms of biological aggressiveness, variegated site of origin (although they are most commonly gastro-entero-pancreatic in about 60% of the cases and pulmonary in approximately 30% of the cases) and capability to potentially produce hormonally active substances poses unique challenges for clinical management. NETs are characterized by the peculiar and frequent expression on the cell surfaces of somatostatin receptors, which represents the ideal target for therapy (i.e., somatostatin analogues (SSAs) and peptide–receptor radionuclide therapy (PRRT)). Few chemotherapy schemes (such as streptozotocin/5-FU or the association of capecitabine and temozolomide) are currently part of the therapeutic armamentarium. However, regardless of the huge number of clinical trials and many promising new drugs, the only approved targeted agents for advanced progressive NETs are everolimus and sunitinib (the second one only for those of pancreatic origin). Additionally, despite great efforts in the search for innovative biomarkers, only few validated biomarkers are available thus far. Following the success of the first volume of “Neuroendocrine Tumors: Challenges and Future Perspectives” (https://www.mdpi.com/journal/jcm/special_issues/Neuroendocrine_Tumors_Perspectives), a second volume of this Special Issue is announced here with the aim to highlight recent advances in the context of diagnosis, treatment and prediction of prognosis for NETs.

Dr. Anna La Salvia
Dr. Giuseppe Lamberti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• neuroendocrine tumors
• clinical challenges
• innovative biomarkers
• novel agents
• personalized oncology

• Neuroendocrine Tumors: Challenges and Future Perspectives in Journal of Clinical Medicine (10 articles)